[High-density lipoprotein: a new target in the battle against atherothrombotic disease].
A low level of high-density lipoprotein (HDL) cholesterol is an important cardiovascular risk factor. The protective effects of HDL have been attributed to its promotion of reverse cholesterol transport, antioxidant activity and anti-inflammatory actions on endothelial cells. Several treatment strategies aimed at exploiting the favourable effects of HDL are currently undergoing clinical trials and hold considerable promise as a novel approach to atheroprotection.
Kardiologisk Laboratorium P, Amtssygehuset i Gentofte, DK-2900 Hellerup. prh@dadlnet.dk
Peter Riis
PR
Hansen
D000818:Animals; D016632:Apolipoprotein A-I / Q000008:administration & dosage / Q000235:genetics; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL / Q000097:blood*; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*
D016632:Apolipoprotein A-I; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D008078:Cholesterol, LDL; D006023:Glycoproteins; D000960:Hypolipidemic Agents